OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
CDMOs adopt flexible processes for manufacturing investigational drug products.
Outsourcing companies fill the gap in drug development and manufacturing.
Liquid and lyophilized forms and preparing for the large capacity present challenges.
March 01, 2021
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
February 22, 2021
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
PathoQuest will apply its experience in viral safety testing and quality control of biologics for mitigating the risk of adventitious agent contamination in biopharmaceutical manufacturing.
February 01, 2021
CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.
January 28, 2021
Nexelis’ recent acquisition of GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory expands its bioanalytical capabilities.
The £500,000 (US$686,294)-investment in mass spectrometry support will accelerate biologics development and approval.
Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.
January 11, 2021
A strategic separation is designed to enhance the value and growth of Paraxel’s contract research services and Calyx’s imaging businesses.
January 06, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
January 02, 2021
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
January 01, 2021
Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.
December 10, 2020
Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.
December 09, 2020
The company is investing in expansion at four sites in the United States, United Kingdom, and Italy, which will include construction of new facilities and addition of sterile and lyophilized filling lines.
Cytiva is adding process development, media and assay development, and contract development services at its facilities in Korea, Japan, Sweden, and the UK.
December 01, 2020
CDMOs strive for flexible, adaptable processes and fast tech transfer for manufacturing investigational drug products, including COVID-19 treatments and vaccines
November 23, 2020
The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.